Ascendis Pharma A/S (NASDAQ:ASND) Price Target Lowered to $174.00 at JPMorgan Chase & Co.

Ascendis Pharma A/S (NASDAQ:ASND) had its price target lowered by JPMorgan Chase & Co. from $180.00 to $174.00 in a research note published on Wednesday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock.

ASND has been the subject of a number of other research reports. TD Cowen raised their price target on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday. Jefferies Financial Group raised their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. Citigroup raised their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Wells Fargo & Company raised their price objective on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Finally, Bank of America raised their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $195.92.

Ascendis Pharma A/S Stock Down 1.1 %

Shares of NASDAQ:ASND opened at $127.69 on Wednesday. Ascendis Pharma A/S has a 52-week low of $85.38 and a 52-week high of $161.00. The company has a 50 day moving average of $135.09 and a two-hundred day moving average of $134.69. The company has a market capitalization of $7.44 billion, a price-to-earnings ratio of -13.29 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. On average, equities analysts anticipate that Ascendis Pharma A/S will post -7.2 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of hedge funds have recently added to or reduced their stakes in ASND. Price T Rowe Associates Inc. MD lifted its stake in Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Ascendis Pharma A/S by 1,461.1% during the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock valued at $37,849,000 after purchasing an additional 234,446 shares during the period. Avoro Capital Advisors LLC increased its holdings in shares of Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after purchasing an additional 229,995 shares during the period. Fred Alger Management LLC increased its holdings in shares of Ascendis Pharma A/S by 65.0% during the second quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after purchasing an additional 120,952 shares during the period. Finally, Tri Locum Partners LP increased its holdings in shares of Ascendis Pharma A/S by 102.1% during the second quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company’s stock valued at $31,062,000 after purchasing an additional 115,092 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.